{"protocolSection": {"identificationModule": {"nctId": "NCT00232583", "orgStudyIdInfo": {"id": "1003-623"}, "organization": {"fullName": "University of Texas Southwestern Medical Center", "class": "OTHER"}, "briefTitle": "Preservation of Beta-cell Function in Type 2 Diabetes Mellitus", "officialTitle": "Preservation of Beta-cell Function in Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2017-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2003-11"}, "primaryCompletionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-30", "studyFirstSubmitQcDate": "2005-09-30", "studyFirstPostDateStruct": {"date": "2005-10-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-10-15", "resultsFirstSubmitQcDate": "2015-05-26", "resultsFirstPostDateStruct": {"date": "2015-05-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-11-17", "lastUpdatePostDateStruct": {"date": "2017-12-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ildiko Lingvay", "investigatorTitle": "MD, MPH, MSCS", "investigatorAffiliation": "University of Texas Southwestern Medical Center"}, "leadSponsor": {"name": "University of Texas Southwestern Medical Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.", "detailedDescription": "This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function, as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["TYpe 2 diabetes mellitus", "Newly diagnosed", "Beta-cell function"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 58, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metfomin and Insulin", "type": "ACTIVE_COMPARATOR", "description": "Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration", "interventionNames": ["Drug: Metformin", "Drug: Insulin"]}, {"label": "Metformin, Pioglitazone and Glyburide", "type": "ACTIVE_COMPARATOR", "description": "Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration", "interventionNames": ["Drug: Metfomin", "Drug: Pioglitazone", "Drug: glyburide"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "Metformin 1000mg/BID", "armGroupLabels": ["Metfomin and Insulin"]}, {"type": "DRUG", "name": "Insulin", "description": "Insulin Novolg 70/30 per protocol titration", "armGroupLabels": ["Metfomin and Insulin"]}, {"type": "DRUG", "name": "Metfomin", "description": "Metformin 1000mg/BID", "armGroupLabels": ["Metformin, Pioglitazone and Glyburide"]}, {"type": "DRUG", "name": "Pioglitazone", "description": "Pioglitazone 45mg", "armGroupLabels": ["Metformin, Pioglitazone and Glyburide"]}, {"type": "DRUG", "name": "glyburide", "description": "Glyburide per protocol titration", "armGroupLabels": ["Metformin, Pioglitazone and Glyburide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Beta-cell Function - C-peptide AUC (Area Under the Curve)", "description": "C-peptide AUC during a 3-hours mixed meal challenge testing", "timeFrame": "72 months"}], "secondaryOutcomes": [{"measure": "Insulin Sensitivity as Measure be Matsuda Index", "description": "C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square \\[(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity.", "timeFrame": "72 months"}, {"measure": "Bet-cell Function Measured by Disposition Index", "description": "Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity", "timeFrame": "72 months"}, {"measure": "Weight", "description": "Body Weight", "timeFrame": "72 months"}, {"measure": "Inflammatory Markers - hsCRP", "description": "Inflammatory markers - hsCRP (C reactive protein)", "timeFrame": "72 months"}, {"measure": "Inflammatory Markers -Fibrinogen", "description": "Inflammatory markers - Fibrinogen", "timeFrame": "72 months"}, {"measure": "Inflammatory Markers - PAI-1", "description": "Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1)", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Current Health Perception", "description": "Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Treatment Satisfaction", "description": "Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Treatment Impact", "description": "Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Social or Vocational Worry", "description": "Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Hypoglycemia Fear", "description": "Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Glycemia Control Perception", "description": "Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Lifestyle Flexibility", "description": "Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Social Stigma", "description": "Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment", "description": "Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.", "timeFrame": "72 months"}, {"measure": "Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment", "description": "Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.", "timeFrame": "72 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* type 2 diabetes mellitus diagnosed within the prior 2 months\n* HbA1c \\> 7% at the time of inclusion\n* willing to perform intensive diabetes management\n* able to comply with treatment and follow-up regimen\n\nExclusion Criteria:\n\n* HbA1c \\> 8% at time of randomization\n* creatinine \\> 1.5 mg/dl\n* liver function tests \\> 3 times the upper limit of normal\n* severe anemia\n* severe proliferative retinopathy\n* NYHA class III or IV heart failure\n* active CAD or recent (within 6 months) MI\n* pregnant, willing to get pregnant, or not willing to practice any contraceptive method\n* non-english speaking\n* active heavy alcohol or illicit drug users (within past 6 months)\n* history of lactic acidosis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "25 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Philip Raskin, MD", "affiliation": "University of Texas", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ildiko Lingvay, MD", "affiliation": "University of Texas", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Texas Southwestern", "city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}]}, "referencesModule": {"references": [{"pmid": "17362692", "type": "RESULT", "citation": "Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007 Mar;55(2):62-8. doi: 10.2310/6650.2007.06036."}, {"pmid": "22723578", "type": "DERIVED", "citation": "Harrison LB, Adams-Huet B, Raskin P, Lingvay I. beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012 Jul;35(7):1406-12. doi: 10.2337/dc11-2170."}, {"pmid": "19592630", "type": "DERIVED", "citation": "Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care. 2009 Oct;32(10):1789-95. doi: 10.2337/dc09-0653. Epub 2009 Jul 10."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A 3-months run-in period preceeded randomization. During this period all patients were treated with insulin and metformin.", "recruitmentDetails": "Patients recruited at UT Southwestern Clinical Diabetes Research Office", "groups": [{"id": "FG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "FG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "13"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "BG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "58"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "58"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.8", "spread": "9.7"}, {"groupId": "BG001", "value": "45.0", "spread": "10.7"}, {"groupId": "BG002", "value": "44.9", "spread": "10.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "37"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "58"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Beta-cell Function - C-peptide AUC (Area Under the Curve)", "description": "C-peptide AUC during a 3-hours mixed meal challenge testing", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*min/mL", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metformin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metformin, GLyburide & Pioglitazone", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2096", "spread": "795"}, {"groupId": "OG001", "value": "1725", "spread": "618"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Sensitivity as Measure be Matsuda Index", "description": "C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square \\[(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "index", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.12", "spread": "2.62"}, {"groupId": "OG001", "value": "2.45", "spread": "1.09"}]}]}]}, {"type": "SECONDARY", "title": "Bet-cell Function Measured by Disposition Index", "description": "Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "index", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.07"}, {"groupId": "OG001", "value": "0.16", "spread": "0.09"}]}]}]}, {"type": "SECONDARY", "title": "Weight", "description": "Body Weight", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin and Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metformin, Pioglitazone and Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "107.7", "spread": "31.1"}, {"groupId": "OG001", "value": "107.9", "spread": "31.4"}]}]}]}, {"type": "SECONDARY", "title": "Inflammatory Markers - hsCRP", "description": "Inflammatory markers - hsCRP (C reactive protein)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/L", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "spread": "7.7"}, {"groupId": "OG001", "value": "6.1", "spread": "8.9"}]}]}]}, {"type": "SECONDARY", "title": "Inflammatory Markers -Fibrinogen", "description": "Inflammatory markers - Fibrinogen", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "399.0", "spread": "82.6"}, {"groupId": "OG001", "value": "395.4", "spread": "98.5"}]}]}]}, {"type": "SECONDARY", "title": "Inflammatory Markers - PAI-1", "description": "Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.9", "spread": "11.7"}, {"groupId": "OG001", "value": "16.7", "spread": "18.0"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Current Health Perception", "description": "Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "0.9"}, {"groupId": "OG001", "value": "2.9", "spread": "0.9"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Treatment Satisfaction", "description": "Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "0.5"}, {"groupId": "OG001", "value": "2.1", "spread": "0.8"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Treatment Impact", "description": "Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a sale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "0.2"}, {"groupId": "OG001", "value": "1.8", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Social or Vocational Worry", "description": "Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.3"}, {"groupId": "OG001", "value": "1.7", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Hypoglycemia Fear", "description": "Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.3"}, {"groupId": "OG001", "value": "1.8", "spread": "0.4"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Glycemia Control Perception", "description": "Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "2.8"}, {"groupId": "OG001", "value": "2.0", "spread": "2.0"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Lifestyle Flexibility", "description": "Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "0.6"}, {"groupId": "OG001", "value": "2.0", "spread": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Social Stigma", "description": "Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}, {"id": "OG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "1.2"}, {"groupId": "OG001", "value": "2.2", "spread": "1.7"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment", "description": "Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.", "populationDescription": "Data were not collected from participants in the \"Metfomin, Pioglitazone \\& Glyburide\" Arm/Group since patients did not receive insulin.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "0.9"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment", "description": "Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.", "populationDescription": "Data were not collected from participants in the \"Metfomin, Pioglitazone \\& Glyburide\" Arm/Group since patients did not receive insulin.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "72 months", "groups": [{"id": "OG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "0.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Metfomin & Insulin", "description": "Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar \\< 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).", "seriousNumAffected": 1, "seriousNumAtRisk": 29, "otherNumAffected": 5, "otherNumAtRisk": 29}, {"id": "EG001", "title": "Metfomin, Pioglitazone & Glyburide", "description": "Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).", "seriousNumAffected": 1, "seriousNumAtRisk": 29, "otherNumAffected": 6, "otherNumAtRisk": 29}], "seriousEvents": [{"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Cardiac arrest leading to sudden death.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 29}]}], "otherEvents": [{"term": "GI disturbance", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Gastrointestinal adverse events included the following conditions: nausea, diarrhea, flatulence and or vomiting. These events were not reported separately.", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 5, "numAtRisk": 29}, {"groupId": "EG001", "numEvents": 18, "numAffected": 6, "numAtRisk": 29}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Relatively small trial, but longest (6-year) follow-up."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Ildiko Lingvay", "organization": "UT Southwestern Medical Center", "email": "ildiko.lingvay@utsouthwestern.edu", "phone": "214-648-2779"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "D000005905", "term": "Glyburide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M29801", "name": "Insulin Aspart", "relevance": "LOW"}, {"id": "M9017", "name": "Glyburide", "asFound": "Lumefantrine", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}